Qingdao Baheal Medical Inc. Class A

Qingdao Baheal Medical Inc. Class A

SSZSE:301015
23.71
CNY
-1.11
(-4.47%)
0.61EPS
56.50P/E
13.50BMarket Cap
Apr 27Next Earn
Qingdao Baheal Medical Inc. Class A
SZSE:301015
(Shenzhen Stock Exchange)

Recent

price

23.71

P/E

ratio

56.50

div

yld

3.07%

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
5.06
6.43
6.55
7.78
10.17
12.5
14.22
14.23
15.77
15.45
14.23
13.56
Revenue per Share
0.15
0.39
0.47
0.55
0.44
0.58
0.85
0.96
1.36
1.32
0.9
0.45
Basic EPS, GAAP
- -
- -
0.32
0.08
0.08
-0.28
0.31
0.38
1.17
0.97
1.22
- -
Free Cash Flow per Basic Share
0.16
0.03
0.15
0.35
0.11
0.32
0.11
0.76
0.84
0.86
0.89
0.73
Dividend per Share
1.73
1.61
1.98
2.28
2.71
3.12
4.11
4.38
5.5
4.52
4.69
4.61
Book Value per Share
1.63
1.52
1.88
2.18
2.63
3.04
4.04
4.27
5.03
3.87
4.04
3.91
Tangible Book Value per Share
473
472
472
469
477
470
496
528
524
524
527
523
Basic Weighted Avg Shares
2,392
3,034
3,096
3,652
4,849
5,879
7,052
7,510
8,256
8,094
7,507
7,098
Sales/Revenue/Turnover
2.04
7.2
8.43
9.56
100
7.42
8.66
9.93
13.35
12.54
10.73
8.55
Operating Margin (%)
- -
- -
19
20
116
20
41
56
86
86
119
- -
Depreciation Expense
73
184
222
258
210
273
422
507
712
692
475
238
Net Income, GAAP
17.31
22.82
24.89
24.38
27.87
25.25
26.6
26.73
25.03
20.65
20.89
22.82
Effective Tax Rate (%)
3.05
6.06
7.17
7.07
4.33
4.64
5.98
6.75
8.62
8.54
6.32
3.35
Profit Margin (%)
405
333
665
619
861
1,029
1,691
1,654
2,727
1,853
1,740
1,599
Working Capital
- -
- -
135
- -
- -
35
22
145
859
1,215
1,363
1,407
LT Debt
818
754
956
1,085
1,305
1,499
2,174
2,279
3,119
2,605
2,742
2,753
Total Equity
- -
12.92
13.17
13.44
10.01
10.36
13.01
13.89
18.83
16.02
10.4
5.22
Return on Invested Capital (%)
- -
15.27
21.7
24.72
20.84
13.46
15.02
16.13
17.06
14.21
8.27
3.92
Return on Capital (%)
- -
23.32
26.16
25.67
17.82
19.81
23.24
22.72
27.43
26.27
19.62
10.36
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,455
2,409
2,479
LT Borrowings
1,253
1,315
1,306
LT Finance Leases
105
99
101
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
526
526
526
Market Capitalization
12,657
10,018
13,498

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
6,114
5,445
5,566
Cash, Cash Equivalents & STI
2,743
2,169
2,209
Accounts Receivable, Net
1,357
1,328
1,272
Inventories
1,085
1,176
1,181
Total Current Liabilities
4,278
3,809
3,967
Payables & Accruals
- -
- -
- -
ST Debt
2,455
2,409
2,479
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.31%
15.11%
5.27%
Free Cash Flow
- -
6.16%
26.61%
Net Income, GAAP
28.18%
16.22%
-31.36%
Sales/Revenue/Turnover
12.8%
5.43%
-7.26%
Total Cash Common Dividend
110.69%
114.96%
3.94%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,848
1,934
2,549
1,951
8,094
2025
1,841
1,910
- -
1,879
7,507
2026
1,784
1,776
1,659
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.39
0.52
0.1
1.32
2025
0.16
0.15
- -
- -
0.9
2026
0.24
0.19
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.78
0.07
-0.01
0.86
2025
0.03
0.8
- -
0.03
0.89
2026
0.04
0.62
0.03
- -
- -
Business
Qingdao Baheal Medical Inc. Qingdao Baheal Medical Inc. (301015.SZ) engages in the research, development, production, wholesale, retail, and commercialization of pharmaceutical products in China. Founded in 2005 and headquartered in Qingdao, China, the company, a subsidiary of BAHEAL Pharmaceutical Holdings Limited, specializes in modern traditional Chinese medicine and high-end controlled-release formulations; it offers a diverse product matrix including bone health drugs such as vitamin D calcium chewable tablets, digestive drugs, liver disease drugs, urological drugs, diabetes drugs, over-the-counter (OTC) and general health products, OTX and prescription medicines, oncology drugs, and high-end medical devices. Baheal Medical operates through segments encompassing brand operations, pharmaceutical wholesale and distribution, and retail, with R&D and production bases in Qingdao and Shanghai, serving clinical practices nationwide via an extensive sales and marketing network. Recent developments include the 2024 acquisition of a 60.199% stake in Shanghai Baheal Pharma Co., Ltd. for CNY 880 million to integrate resources and extend its industrial chain into pioneering innovations; establishment of Baheal Medical (Guangdong) Co., Ltd. with CNY 50 million capital for medical device leasing and sales; strategic investment in CANbridge Pharmaceuticals Inc. for approximately HK$100 million alongside an exclusive commercial services agreement for rare disease products in mainland China, Hong Kong, and Macau; a partnership with Tianjin Jikun Pharmaceutical Technology Co., Ltd. granting rights to acquire the idiopathic pulmonary fibrosis drug JK1033 and a 24% equity stake; and a commercialization collaboration with Shanghai Roche Pharmaceuticals Ltd. to promote MabThera.